Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer.
Gridelli
C
C
Perrone
F
F
D'Aprile
M
M
Rossi
A
A
Palmeri
S
S
Curcio
C
C
Veltri
E
E
Ianniello
G
G
Lorusso
V
V
Palmieri
G
G
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D016179:Granulocyte Colony-Stimulating Factor; D015251:Epirubicin; D005047:Etoposide; D003520:Cyclophosphamide; D016190:Carboplatin; D002330:Carmustine